Lantern Pharma ( (LTRN) ) has issued an announcement.
On March 27, 2025, Lantern Pharma announced its financial results for the fourth quarter and full year ended December 31, 2024, alongside updates on its AI-driven drug candidates and operational progress. The company reported significant advancements in its clinical programs, including the HARMONIC™ trial for LP-300, which showed promising results in never-smoker NSCLC patients, and the continued progress of LP-184 and LP-284 in clinical trials. Lantern Pharma also highlighted its innovative AI capabilities, such as the RADR® platform surpassing 100 billion oncology-specific data points and the development of an AI-powered ADC module, which could significantly reduce development timelines and costs.
More about Lantern Pharma
Lantern Pharma Inc. is a clinical-stage biopharmaceutical company that leverages its proprietary RADR® artificial intelligence (AI) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development. The company focuses on precision oncology drug development and is a leader in using AI to deliver next-generation cancer medicines.
YTD Price Performance: 10.61%
Average Trading Volume: 88,155
Technical Sentiment Signal: Strong Buy
Current Market Cap: $41.52M
See more insights into LTRN stock on TipRanks’ Stock Analysis page.